148 related articles for article (PubMed ID: 36826106)
41. Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Catenacci DVT; Kang YK; Yoon HH; Shim BY; Kim ST; Oh DY; Spira AI; Ulahannan SV; Avery EJ; Boland PM; Chao J; Chung HC; Gardner F; Klempner SJ; Lee KW; Oh SC; Peguero J; Sonbol MB; Shen L; Moehler M; Sun J; Li D; Rosales MK; Park H
ESMO Open; 2022 Oct; 7(5):100563. PubMed ID: 36029651
[TBL] [Abstract][Full Text] [Related]
42. Microsatellite Instability Analysis and Its Prognostic Value in Invasive Nonampullary Duodenal Adenocarcinoma.
Yang G; Tanaka T; Kinugasa H; Kanzaki H; Chen MX; Ichimura K; Nakagawa M; Jin ZS; Zheng RY; Yoshino T
Oncology; 2022; 100(5):290-302. PubMed ID: 35350032
[TBL] [Abstract][Full Text] [Related]
43. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
44. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
45. Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Yamashita S; Abe H; Kunita A; Yamashita H; Seto Y; Ushiku T
Histopathology; 2021 Feb; 78(3):381-391. PubMed ID: 32767778
[TBL] [Abstract][Full Text] [Related]
46. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond.
Park R; Da Silva LL; Saeed A
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916348
[TBL] [Abstract][Full Text] [Related]
48. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Giuffrida P; Arpa G; Grillo F; Klersy C; Sampietro G; Ardizzone S; Fociani P; Fiocca R; Latella G; Sessa F; D'Errico A; Malvi D; Mescoli C; Rugge M; Nesi G; Ferrero S; Furlan D; Poggioli G; Rizzello F; Macciomei MC; Santini D; Volta U; De Giorgio R; Caio G; Calabrò A; Ciacci C; D'Armiento M; Rizzo A; Solina G; Martino M; Tonelli F; Villanacci V; Cannizzaro R; Canzonieri V; Florena AM; Biancone L; Monteleone G; Caronna R; Ciardi A; Elli L; Caprioli F; Vecchi M; D'Incà R; Zingone F; D'Odorico A; Lenti MV; Oreggia B; Reggiani Bonetti L; Astegiano M; Biletta E; Cantoro L; Giannone AG; Orlandi A; Papi C; Perfetti V; Quaquarini E; Sandri G; Silano M; Usai P; Barresi V; Ciccocioppo R; Luinetti O; Pedrazzoli P; Pietrabissa A; Viglio A; Paulli M; Corazza GR; Solcia E; Vanoli A; Di Sabatino A
Mod Pathol; 2020 Jul; 33(7):1398-1409. PubMed ID: 32066859
[TBL] [Abstract][Full Text] [Related]
49. Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience.
Salati M; Ghidini M; Paccagnella M; Reggiani Bonetti L; Bocconi A; Spallanzani A; Gelsomino F; Barbin F; Garrone O; Daniele B; Dominici M; Facciorusso A; Petrillo A
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614254
[TBL] [Abstract][Full Text] [Related]
50. Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Jomrich G; Kollmann D; Ramazanova D; Ristl R; Grose RP; Ilhan-Mutlu A; Preusser M; Fassnacht C; Tsai YC; Guenova E; Schoppmann SF
Eur J Surg Oncol; 2022 Feb; 48(2):383-390. PubMed ID: 34404561
[TBL] [Abstract][Full Text] [Related]
51. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.
Guazzo E; Cooper C; Wilkinson L; Feng S; King B; Simpson F; Porceddu S; Panizza B; Coward JIG
Head Neck; 2021 Mar; 43(3):768-777. PubMed ID: 33169486
[TBL] [Abstract][Full Text] [Related]
52. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
53. PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
Roberts J; Salaria SN; Cates J; Wang Y; Vnencak-Jones C; Berlin J; Shi C
Am J Clin Pathol; 2019 Aug; 152(3):384-391. PubMed ID: 31152546
[TBL] [Abstract][Full Text] [Related]
54. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
55. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Hashimoto T; Kurokawa Y; Takahashi T; Miyazaki Y; Tanaka K; Makino T; Yamasaki M; Nakajima K; Ikeda JI; Mori M; Doki Y
Gastric Cancer; 2019 Jul; 22(4):785-792. PubMed ID: 30617648
[TBL] [Abstract][Full Text] [Related]
56. MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma.
van Velzen MJM; Derks S; van Grieken NCT; Haj Mohammad N; van Laarhoven HWM
Cancer Treat Rev; 2020 Jun; 86():102024. PubMed ID: 32388292
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
58. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
59. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
60. Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
Huang D; Zhang F; Tao H; Zhang S; Ma J; Wang J; Liu Z; Cui P; Chen S; Huang Z; Wu Z; Zhao L; Hu Y
Target Oncol; 2020 Feb; 15(1):93-100. PubMed ID: 32052340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
